TCW Group Inc. Makes New $1.29 Million Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

TCW Group Inc. purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to its most recent filing with the SEC. The firm purchased 71,390 shares of the company’s stock, valued at approximately $1,286,000.

Other large investors have also recently made changes to their positions in the company. UMB Bank n.a. grew its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co boosted its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $52,000. Claro Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $57,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $16.81 on Friday. The business’s 50-day simple moving average is $17.51 and its two-hundred day simple moving average is $17.39. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.56 and a fifty-two week high of $19.31.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays raised their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.